Intermediate and posterior uveitis

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 228-243

  Forrester, John V ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BONE MARROW APLASIA; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL THERAPY; CHOROID; DEPRESSION; DISEASE MODEL; DRUG DOSE TITRATION; DRUG SYNTHESIS; EYE INFLAMMATION; EYE INJURY; GENE DELETION; HAIR LOSS; HYPERTENSION; INFECTION; IRIDOCYCLITIS; KIDNEY FAILURE; LASSITUDE; MACROPHAGE; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA VASCULITIS; RETINITIS; RETINOPATHY; SIDE EFFECT; TRANSGENE; UNSPECIFIED SIDE EFFECT; UVEITIS; UVEORETINITIS; VISUAL IMPAIRMENT; VITREOUS BODY; WEIGHT REDUCTION; ANIMAL; CLASSIFICATION; HUMAN; INTERMEDIATE UVEITIS; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; UVEITIS; UVEITIS, INTERMEDIATE; UVEITIS, POSTERIOR;

EID: 33947517320     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099274     Document Type: Article

References (72)

1. Forrester JV, Liversidge J, Dua HS, Towler H, McMenamin PG: Comparison of clinical and experimental uveitis. Curr Eye Res 1990;9(suppl):75-84.
2. Forrester JV, Okada A, BenEzra D, Ohno S: Posterior Segment Intraocular Inflammation: Guidelines. The Hague, Kugler, 1998.
3. Whitcup SM, Nussenblatt RB: Uveitis: Fundamentals and Clinical Practice. St. Louis, Mosby, 2005.
4. Boyd SR, Young S, Lightman S: Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 2001;46:209-233.
5. Bouchenaki N, Cimino L, Auer C, Tao Tran V, Herbort CP: Assessment and classification of choroidal vasculitis in posterior uveitis using indocyanine green angiography. Klin Monatsbl Augenheilkd 2002;219:243-249.
6. Forrester JV: Autoimmunity and autoimmune disease of the eye. Dev Ophthalmol 1999;30:167-186.
7. Forrester JV, McMenamin PG: Immunopathogenic mechanisms in intraocular inflammation; in Streilein JW (ed): Immune Response and the Eye. Chem Immunol. Basel, Karger, 1999, vol 73, pp 159-185.
8. Elschnig A: Studien zur sympathischen Ophhalmis. Die antigene Wirkung des Augenpigmentes. Graefes Arch Ophthalmol 1910;76:509-546.
9. Janeway CA Jr: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992;13:11-16.
10. Stuart JM, Townes AS, Kang AH: Collagen autoimmune arthritis. Annu Rev Immunol 1984;2: 199-218.
11. Wilder RL: Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 1995;13:307-338.
12. Burkhardt H, Kalden JR: Animal models of autoimmune diseases. Rheumatol Int 1997;17:91-99.
13. Wacker WB: Proctor Lecture. Experimental allergic uveitis. Investigations of retinal autoimmunity and the immunopathologic responses evoked. Invest Ophthalmol Vis Sci 1991;32: 3119-3128.
14. Caspi RR: Immunogenetic aspects of clinical and experimental uveitis. Reg Immunol 1992;4: 321-330.
15. Caspi RR: Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 2002;21:197-208.
16. Crane IJ, Forrester JV: Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005;25:75-102.
17. Dick AD, Forrester JV, Liversidge J, Cope AP: The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-637.
18. Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McMenamin PG: Experimental autoimmune uveoretinitis: A model system for immunointervention: A review. Curr Eye Res 1992; 11(suppl):33-40.
19. Yamaki K, Takiyama N, Itho N, Mizuki N, Seiya M, Sinsuke W, Hayakawa K, Kotani T: Experimentally induced Vogt-Koyanagi-Harada disease in two Akita dogs. Exp Eye Res 2005;80: 273-280.
20. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S: Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 2000;165:7323-7329.
21. Bora NS, Sohn JH, Kang SG, Cruz JM, Nishihori H, Suk HJ, Wang Y, Kaplan HJ, Bora PS: Type I collagen is the autoantigen in experimental autoimmune anterior uveitis. J Immunol 2004;172: 7086-7094.
22. Deeg CA, Thurau SR, Gerhards H, Ehrenhofer M, Wildner G, Kaspers B: Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur J Immunol 2002;32:2598-2606.
23. Deeg CA, Ehrenhofer M, Thurau SR, Reese S, Wildner G, Kaspers B: Immunopathology of recurrent uveitis in spontaneously diseased horses. Exp Eye Res 2002;75:127-133.
24. Ichikawa T, Taguchi O, Takahashi T, Ikeda H, Takeuchi M, Tanaka T, Usui M, Nishizuka Y: Spontaneous development of autoimmune uveoretinitis in nude mice following reconstitution with embryonic rat thymus. Clin Exp Immunol 1991;86:112-117.
25. Egwuagu CE, Charukamnoetkanok P, Gery I: Thymic expression of autoantigens correlates with resistance to autoimmune disease. J Immunol 1997;159:3109-3112.
26. Takase H, Yu CR, Mahdi RM, Douek DC, Dirusso GB, Midgley FM, Dogra R, Allende G, Rosenkranz E, Pugliese A, Egwuagu CE, Gery I: Thymic expression of peripheral tissue antigens in humans: A remarkable variability among individuals. Int Immunol 2005;17:1131-1140.
27. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D: Projection of an immunological self shadow within the thymus by the AIRE protein. Science 2002;298:1395-1401.
28. Goldrath AW, Hedrick SM: Central tolerance matters. Immunity 2005;23:113-114.
29. Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D: The cellular mechanism of AIRE control of T cell tolerance. Immunity 2005;23:227-239.
30. Szpak Y, Vieville JC, Tabary T, Naud MC, Chopin M, Edelson C, Cohen JH, Dausset J, de Kozak Y, Pla M: Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci USA 2001;98: 2572-2576.
31. Nussenblatt RB, Mittal KK, Ryan S, Green WR, Maumenee AE: Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94:147-158.
32. Ham DI, Kim SJ, Chen J, Vistica BP, Fariss RN, Lee RS, Wawrousek EF, Takase H, Yu CR, Egwuagu CE, Chan CC, Gery I: Central immunotolerance in transgenic mice expressing a foreign antigen under control of the rhodopsin promoter. Invest Ophthalmol Vis Sci 2004;45: 857-862.
33. Zhang M, Vacchio MS, Vistica BP, Lesage S, Egwuagu CE, Yu CR, Gelderman MP, Kennedy MC, Wawrousek EF, Gery I: T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: The soluble form is more effective than the membrane-bound form. J Immunol 2003;170: 3954-3962.
34. Gregerson DS, Dou C: Spontaneous induction of immunoregulation by an endogenous retinal antigen. Invest Ophthalmol Vis Sci 2002;43:2984-2991.
35. Gregerson DS, Xiao JJ: Failure of memory (CD44 high) CD4 T cells to recognize their target antigen in retina. J Neuroimmunol 2001;120:34-41.
36. McPherson SW, Roberts JP, Gregerson DS: Systemic expression of rat soluble retinal antigen induces resistance to experimental autoimmune uveoretinitis. J Immunol 1999;163: 4269-4276.
37. Gregerson DS, Torseth JW, McPherson SW, Roberts JP, Shinohara T, Zack DJ: Retinal expression of a neo-self antigen, beta-galactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. J Immunol 1999;163:1073-1080.
38. Kapphahn RJ, Ethen CM, Peters EA, Higgins L, Ferrington DA: Modified alpha A crystallin in the retina: Altered expression and truncation with aging. Biochemistry 2003;42:15310-15325.
39. Prendergast RA, Iliff CE, Coskuncan NM, Caspi RR, Sartani G, Tarrant TK, Lutty GA, McLeod DS: T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 1998;39:754-762.
40. Xu H, Forrester JV, Liversidge J, Crane IJ: Leukocyte trafficking in experimental autoimmune uveitis: Breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest Ophthalmol Vis Sci 2003;44:226-234.
41. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ: Requirements for passage of T lymphocytes across non-inflamed retinal microvessels. J Neuroimmunol 2003;142:47-57.
42. Xu H, Manivannan A, Jiang HR, Liversidge J, Sharp PF, Forrester JV, Crane IJ: Recruitment of IFN-gamma-producing (Th1-like) cells into the inflamed retina in vivo is preferentially regulated by P-selectin glycoprotein ligand 1:P/E-selectin interactions. J Immunol 2004;172:3215-3224.
43. Jiang HR, Lumsden L, Forrester JV: Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci 1999;40: 3177-3185.
44. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S: Macrophage receptors and immune recognition. Annu Rev Immunol 2005;23:901-944.
45. Robertson MJ, Erwig LP, Liversidge J, Forrester JV, Rees AJ, Dick AD: Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci 2002;43:2250-2257.
46. Zhang M, Fukushima A, Vistica BP, Kim SJ, Hung L, Wawrousek EF, Egwuagu CE, Lee RS, Whitcup SM, Gery I: Skewed abrogation of tolerance to a neo self-antigen in double-transgenic mice coexpressing the antigen with interleukin-1b or interferon-d. Cell Immunol 2001;207:6-12.
47. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR: IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997;158:5997-6005.
48. Shao H, Fu Y, Liao T, Peng Y, Chen L, Kaplan HJ, Sun D: Anti-CD137mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci 2005;46:596-603.
49. Bagenstose LM, Agarwal RK, Silver PB, Harlan DM, Hoffmann SC, Kampen RL, Chan CC, Caspi RR: Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J Immunol 2005;175:124-130.
50. Crane IJ, Xu H, Manivannan A, McKillop-Smith S, Lamont G, Wallace C, Liversidge J, Sharp PF, Forrester JV: Effect of anti-macrophage inflammatory protein-1 on leukocyte trafficking and disease progression in experimental autoimmune uveoretinitis. Eur J Immunol 2003;33:402-410.
51. Xu H, Manivannan A, Goatman KA, Liversidge J, Sharp PF, Forrester JV, Crane IJ: Improved leukocyte tracking in mouse retinal and choroidal circulation. Exp Eye Res 2002;74:403-410.
52. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ: Involvement of CD44 in leukocyte trafficking at the blood-retinal barrier. J Leukoc Biol 2002;72:1133-1141.
53. Jiang HR, Muckersie E, Robertson M, Xu H, Liversidge J, Forrester JV: Secretion of interleukin-10 or interleukin-12 by LPS-activated dendritic cells is critically dependent on time of stimulus relative to initiation of purified DC culture. J Leukoc Biol 2002;72:978-985.
54. Jiang HR, Muckersie E, Robertson M, Forrester JV: Antigen-specific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells. Invest Ophthalmol Vis Sci 2003;44:1598-1607.
55. Gangi E, Vasu C, Cheatem D, Prabhakar BS: IL-10-producing CD4+ CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol 2005;174:7006-7013.
56. Li Y, Heuser JS, Kosanke SD, Hemric M, Cunningham MW: Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells. Am J Pathol 2005;167:5-15.
57. Mahnke K, EKk AH: Dendritic cells: key cells for the induction of regulatory T cells? Curr Top Microbiol Immunol 2005;293:133-150.
58. Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR: Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 2000;106:245-252.
59. Oksala A: The significance of treatment by antibiotics and steroids in acute anterior uveitis. Acta Ophthalmol (Copenh) 1960;38:405-409.
60. Campbell FP: Retina and optic nerve. Arch Ophthalmol 1968;79:789-802.
61. Dick AD, Kreutzer B, Laliotou B, Forrester JV: Phenotypic analysis of retinal leukocyte infiltration during combined cyclosporin A and nasal antigen administration of retinal antigens: Delay and inhibition of macrophage and granulocyte infiltration. Ocul Immunol Inflamm 1997;5:129-140.
62. Mochizuki M, Kawashima H: Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. Autoimmunity 1990;8:37-41.
63. Caspi RR, McAllister CG, Gery I, Nussenblatt RB: Differential effects of cyclosporins A and G on functional activation of a T-helper-lymphocyte line mediating experimental autoimmune uveoretinitis. Cell Immunol 1988;113:350-360.
64. Liversidge J, Thomson AW, Sewell HF, Forrester JV: EAU in the guinea pig: Inhibition of cell-mediated immunity and Ia antigen expression by cyclosporin A. Clin Exp Immunol 1987;69: 591-600.
65. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD: Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-641.
66. Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD: Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-109.
67. Greiner K, Murphy CC, Willermain F, Duncan L, Plskova J, Hale G, Isaacs JD, Forrester JV, Dick AD: Anti-TNF therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 2004;45:170-176.
68. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, Rebello P, Waldmann H, Hale G, Forrester JV, Dick AD: Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004;122:845-851.
69. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N: Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87: 423-431.
70. Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV: Interferon-alpha: A key factor in autoimmune disease? Invest Ophthalmol Vis Sci 2006;47:3946-3950.
71. Kotter I, Deuter C, Stubiger N, Zierhut M: Interferon-α (IFN-α) application versus tumor necrosis factor-α antagonism for ocular Behçet's disease: Focusing more on IFN. J Rheumatol 2005;32: 1633-1634.
72. Jabs DA, Nussenblatt RB, Rosenbaum JT: Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.